DrugPatentWatch Database Preview
Email this page to a colleague
« Back to Dashboard
PLX3397 is an investigational drug.
There have been 24 clinical trials for PLX3397. The most recent clinical trial was a Phase 2 trial, which was initiated on September 3rd 2020.
The most common disease conditions in clinical trials are Giant Cell Tumors, Melanoma, and Giant Cell Tumor of Tendon Sheath. The leading clinical trial sponsors are Plexxikon, Daiichi Sankyo Co., Ltd., and National Cancer Institute (NCI).
There are fifty-two US patents protecting this investigational drug and three hundred and ninety-one international patents.
Recent Clinical Trials for PLX3397
|A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan||Daiichi Sankyo Co., Ltd.||Phase 2|
|A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT||Daiichi Sankyo Co., Ltd.||Phase 3|
|Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib||Daiichi Sankyo, Inc.||Phase 4|
Top disease conditions for PLX3397
Top clinical trial sponsors for PLX3397
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|PLX3397||Get Started Free||Synthesis of a compound that modulates kinases||Plexxikon Inc. (Berkeley, CA) Daiichi Sankyo Company, Limited (Tokyo, JP)||Get Started Free|
|PLX3397||Get Started Free||Solid forms of (1S,4S)-4-(2-(((3S,4R)-3-fluorotetrahydro-2H-pyran-4-yl)amino)-8-((2,4,6-- trichlorophenyl)amino)-9H-purin-9-yl)-1-methylcyclohexane-1-carboxamide and methods of their use||Signal Pharmaceuticals, LLC (San Diego, CA)||Get Started Free|
|PLX3397||Get Started Free||Formulations of 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)m- ethyl)-2,2-difluoroacetamide||Celgene Corporation (Summit, NJ)||Get Started Free|
|PLX3397||Get Started Free||Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation||AB SCIENCE (Paris, FR)||Get Started Free|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|PLX3397||Australia||AU2016258027||2035-05-06||Get Started Free|
|PLX3397||Brazil||BR112017023490||2035-05-06||Get Started Free|
|PLX3397||Brazil||BR112017023540||2035-05-06||Get Started Free|
|PLX3397||Canada||CA2984899||2035-05-06||Get Started Free|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|